Skip to content
Anastrozole
Arimidex (anastrozole) is a small molecule pharmaceutical. Anastrozole was first approved as Arimidex on 1995-12-27. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against aromatase.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Arimidex (generic drugs available since 2010-06-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Anastrozole
Tradename
Company
Number
Date
Products
ARIMIDEXANI PHARMSN-020541 RX1995-12-27
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
anastrozoleANDA2023-05-01
arimidexNew Drug Application2019-10-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
breast neoplasmsEFO_0003869D001943C50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L02: Endocrine therapy antineoplastic and immunomodulating agents
L02B: Hormone antagonists and related agents
L02BG: Aromatase inhibitors
L02BG03: Anastrozole
HCPCS
Code
Description
S0170
Anastrozole, oral, 1 mg
Clinical
Clinical Trials
277 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501693571028198
Male breast neoplasmsD018567521210
HypogonadismD007006E23.013217
Invasive hydatidiform moleD002820D39.221216
ObesityD009765EFO_0001073E66.91236
EndometriosisD004715EFO_0001065N801124
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD0647268412
NeoplasmsD009369C805318
Ductal carcinoma breastD01827022
GynecomastiaD006177HP_0000771N62112
Progression-free survivalD00007798211
Bone densityD015519EFO_0003923M8511
OligospermiaD009845N46.111
HypopituitarismD007018EFO_0001380E23.0111
Klinefelter syndromeD007713EFO_1001006Q98.011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients81110
Endometrial neoplasmsD016889EFO_0004230245
Ovarian neoplasmsD010051EFO_0003893C56134
Metabolic syndromeD024821EFO_0000195E88.811113
Non-small-cell lung carcinomaD002289112
Pulmonary arterial hypertensionD00008102922
Intraductal carcinoma noninfiltratingD002285D05.122
EunuchismD005058EFO_0007266E29.111
Bone neoplasmsD001859EFO_0003820D1611
Peritoneal neoplasmsD01053411
Show 16 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10112
Kallmann syndromeD017436Orphanet_478E23.011
Breast densityD00007106011
PharmacokineticsD01059911
AgingD000375GO_0007568R41.8111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ArthralgiaD018771HP_0002829M25.555
PainD010146EFO_0003843R5211
Prader-willi syndromeD011218Orphanet_739Q87.1111
Silver-russell syndromeD056730Orphanet_813Q87.1911
Insulin resistanceD007333EFO_000261411
Vitamin d deficiencyD014808EFO_0003762E5511
Drug-related side effects and adverse reactionsD064420T88.711
Nutrition disordersD009748EFO_000106911
Musculoskeletal painD05935211
ArthritisD001168EFO_0005856M05-M1411
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameANASTROZOLE
INNanastrozole
Description
Anastrozole is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile.
Classification
Small molecule
Drug classaromatase inhibitors (imidazole/triazole derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
Identifiers
PDB
CAS-ID120511-73-1
RxCUI84857
ChEMBL IDCHEMBL1399
ChEBI ID2704
PubChem CID2187
DrugBankDB01217
UNII ID2Z07MYW1AZ (ChemIDplus, GSRS)
Target
Agency Approved
CYP19A1
CYP19A1
Organism
Homo sapiens
Gene name
CYP19A1
Gene synonyms
ARO1, CYAR, CYP19
NCBI Gene ID
Protein name
aromatase
Protein synonyms
CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, cytochrome P450, family 19, subfamily A, polypeptide 1, cytochrome P450, subfamily XIX (aromatization of androgens), Estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Uniprot ID
Mouse ortholog
Cyp19a1 (13075)
aromatase (P28649)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Arimidex - AstraZeneca
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,811 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,274 adverse events reported
View more details